摘要
目的:探讨维格列汀联合二甲双胍对新诊断2型糖尿病的疗效及对微炎性状态的影响。方法:选取2016年4月-2018年4月本院80例新诊断2型糖尿病患者为研究对象,根据随机数字表法分为对照组(二甲双胍组)40例和观察组(维格列汀联合二甲双胍组)40例。比较两组患者的血糖控制总有效率、治疗前后的血糖及糖化血红蛋白(HbA1c)、血清微炎性指标的差异。结果:观察组的血糖控制总有效率高于对照组,差异有统计学意义(P<0.05),治疗前两组的血糖及HbA1c、血清微炎性指标比较,差异均无统计学意义(P>0.05),治疗后观察组的血糖及HbA1c、血清微炎性指标均低于对照组,差异均有统计学意义(P<0.05)。结论:维格列汀联合二甲双胍对新诊断2型糖尿病的疗效较好,更有效地抑制机体的微炎性状态,因此在新诊断2型糖尿病中具有较高的应用价值。
Objective:To investigate the effect of Vildagliptin combined with Metformin in the treatment of newly diagnosed type 2 diabetes mellitus and influence for the micro-inflammatory state.Method:80 patients with newly diagnosed type 2 diabetes mellitus from April 2016 to April 2018 were selected as the study objects,and they were divided into control group(Metformin)40 cases and observation group(Vildagliptin combined with Metformin)40 cases according to the method of random number table.The total effective rates of blood glucose control,blood glucose,glycosylated hemoglobin(HbA1 c)and serum micro-inflammatory indexes before and after the treatment of two groups were compared.Result:The total effective rates of blood glucose control in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).The blood glucose,HbA1 c and serum micro-inflammatory indexes of two groups before the treatment were compared,the differences were not statistically significant(P>0.05).The blood glucose,HbA1 c and serum micro-inflammatory indexes of observation group after the treatment were all lower than those of control group,the differences were statistically significant(P<0.05).Conclusion:The effect of Vildagliptin combined with Metformin in the patients with newly diagnosed type 2 diabetes mellitus is better,and can more effectively inhibit the micro-inflammatory state of the body,so its application value in the patients with newly diagnosed type2 diabetes mellitus is higher.
作者
冯毅
FENG Yi(People’s Hospital of Zhongshan City,Zhongshan 528403,China)
出处
《中国医学创新》
CAS
2019年第15期110-113,共4页
Medical Innovation of China
基金
中山市科技计划项目(2017B1069)
关键词
维格列汀
二甲双胍
2型糖尿病
微炎性状态
Vildagliptin
Metformin
Type 2 diabetes mellitus
Micro-inflammatory state